Acarix announces enrollment of first patient in US-based Clinical Workflow Evaluation Study

Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce the enrollment of the first patient in its first US-based clinical study. The study aims to gather real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States.

The study is set to enroll 200 patients at the University of California, Davis, assessing the potential improvements in cost-effectiveness, time savings, and reduction in side effects by using the CADScor System compared to traditional stress imaging tests. This marks a crucial step in enhancing the understanding of the CADScor System's role in various clinical workflows across the United States.

"I am thrilled to announce the enrollment of the first patient in our US-based study," stated Acarix President & CEO Aamir Mahmood. "This study has the potential to transform the rapid assessment of non-obstructive CAD, streamline ER processes, and establish a protocol at UC Davis and emergency departments nationwide for safely discharging low-risk chest pain patients.”

For more information contact:
Jennifer Anderson, Head of Marketing & Communications, phone [phone], email [e-mail] 

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments
Acarix announces enrollment of first patient in US-based Clinical Workflow Evaluation Study

© Modular Finance, source Nordic Press Releases